LivaNova PLC (NASDAQ:LIVN) Stock Holdings Increased by Trexquant Investment LP

Trexquant Investment LP raised its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 139.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 101,653 shares of the company’s stock after buying an additional 59,241 shares during the period. Trexquant Investment LP owned about 0.19% of LivaNova worth $4,708,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in LIVN. Xponance Inc. grew its holdings in shares of LivaNova by 6.1% in the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after acquiring an additional 445 shares during the last quarter. Swiss National Bank increased its stake in LivaNova by 0.7% in the 4th quarter. Swiss National Bank now owns 106,819 shares of the company’s stock worth $4,947,000 after purchasing an additional 700 shares in the last quarter. Central Pacific Bank Trust Division raised its holdings in LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after buying an additional 720 shares during the period. Amalgamated Bank lifted its stake in LivaNova by 3.0% during the fourth quarter. Amalgamated Bank now owns 24,900 shares of the company’s stock valued at $1,153,000 after buying an additional 729 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of LivaNova by 0.5% in the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock worth $8,240,000 after buying an additional 899 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

LIVN has been the subject of several research analyst reports. Barclays reduced their price target on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating for the company in a research report on Friday, March 7th. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and set a $64.00 price target on shares of LivaNova in a research report on Monday, March 17th. The Goldman Sachs Group decreased their price objective on LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Finally, Mizuho reduced their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, LivaNova currently has a consensus rating of “Buy” and a consensus price target of $61.17.

LivaNova Trading Down 4.1 %

NASDAQ:LIVN opened at $35.95 on Friday. The company has a market capitalization of $1.95 billion, a P/E ratio of 85.60 and a beta of 0.90. The stock’s 50 day moving average price is $43.47 and its 200 day moving average price is $48.10. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova PLC has a 52 week low of $35.24 and a 52 week high of $64.48.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.